IShares Pharmaceuticals is trading at 66.15 as of the 18th of January 2025, a 1.42 percent decrease since the beginning of the trading day. The etf's lowest day price was 66.15. IShares Pharmaceuticals has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 18th of January 2025. Click here to learn more.
The fund generally will invest at least 80 percent of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. More on iShares Pharmaceuticals ETF
Diane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason
Transfer Agent
Citibank, N.A.
Fiscal Year End
31-Mar
Exchange
NYSE Arca, Inc.
Number of Constituents
46.0
Market Maker
Latour Trading
Total Expense
0.4
Management Fee
0.4
Country Name
USA
Returns Y T D
0.65
Name
iShares U.S. Pharmaceuticals ETF
Currency Code
USD
Open Figi
BBG000P8JWT2
In Threey Volatility
14.78
1y Volatility
13.88
200 Day M A
67.9537
50 Day M A
67.469
Code
IHE
Updated At
18th of January 2025
Currency Name
US Dollar
iShares Pharmaceuticals ETF [IHE] is traded in USA and was established 2006-05-01. The fund is classified under Health category within iShares family. The entity is thematically classified as Sector ETFs. iShares Pharmaceuticals currently have 381.08 M in assets under management (AUM). , while the total return for the last 3 years was 2.7%.
Check IShares Pharmaceuticals Probability Of Bankruptcy
The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in IShares Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures.
When determining whether iShares Pharmaceuticals is a strong investment it is important to analyze IShares Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact IShares Pharmaceuticals' future performance. For an informed investment choice regarding IShares Etf, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iShares Pharmaceuticals ETF. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in rate.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
The market value of iShares Pharmaceuticals is measured differently than its book value, which is the value of IShares that is recorded on the company's balance sheet. Investors also form their own opinion of IShares Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is IShares Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IShares Pharmaceuticals' market value can be influenced by many factors that don't directly affect IShares Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IShares Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if IShares Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IShares Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.